Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Moderate Buy” by Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $137.3125.

A number of analysts recently weighed in on MIRM shares. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $165.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research report on Monday, June 15th. Wolfe Research initiated coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target for the company. Finally, TD Cowen lowered their price objective on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Thursday, August 6th.

Mirum Pharmaceuticals Trading Up 0.6%

MIRM stock opened at $98.05 on Tuesday. The company has a market cap of $6.37 billion, a price-to-earnings ratio of -6.74 and a beta of 0.52. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The business has a fifty day simple moving average of $110.44 and a 200-day simple moving average of $101.78. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same period last year, the company posted ($0.12) EPS. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. On average, equities research analysts expect that Mirum Pharmaceuticals will post -1.31 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the sale, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $23,758,161.43. The trade was a 9.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 103,156 shares of company stock valued at $10,888,362 in the last ninety days. Insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after acquiring an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Mirum Pharmaceuticals by 7.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after acquiring an additional 1,720 shares in the last quarter. Caxton Associates LLP acquired a new position in Mirum Pharmaceuticals in the first quarter worth $217,000. Finally, Empowered Funds LLC boosted its holdings in Mirum Pharmaceuticals by 15.4% in the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.